Product Description
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Asthma|Asthma, Exercise-Induced
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GRC 3886-201 | P2 |
Unknown status |
Asthma |
2009-12-01 |
|
GRC-MD-50 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-05-15 |
|
GRC-MD-03 | P2 |
Completed |
Asthma |
2006-12-01 |
|
GRC-MD-01 | P2 |
Completed |
Asthma, Exercise-Induced |
2006-10-01 |